Special Issue

Personalized Pharmacological Treatment in Schizophrenia: The Role of New Antipsychotics

Message from the Guest Editor

Schizophrenia is a severe mental illness.

Pharmacological therapy represents the cornerstone for a successful intervention. Antipsychotic drugs differ in terms of efficacy and tolerability for individual patients and should be administered in conjunction with appropriate psychosocial and rehabilitation interventions. It is therefore necessary to identify and know the techniques of personalization of the therapy, which take into account clinical dimensions, such as negative and cognitive symptoms, and other variables, such as tolerability, adherence, psychosocial functioning, and patient preference.

This Special Issue will provide an update on pharmacological treatments for schizophrenia, from the acute phase to the maintenance and rehabilitation phase, and on the best strategies to provide each patient with a therapy that is based on the latest scientific evidence and, at the same time, adapted to the needs of individual people.

Particular attention will be paid to the need to find a favorable balance between efficacy, tolerability, and adherence to treatment.

Guest Editor

Dr. Stefano Barlati

- 1. Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy
- 2. Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy

Deadline for manuscript submissions

closed (25 July 2022)



Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.6
Indexed in PubMed



mdpi.com/si/108405

Brain Sciences
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
brainsci@mdpi.com

mdpi.com/journal/ brainsci





Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 5.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

